BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37061177)

  • 1. Prevalence and treatment of anemia and secondary iron overload in patients with a myelodysplastic syndrome: Real-world data from a multicenter cohort study.
    de Roij van Zuijdewijn CLM; Westerweel PE; Schipperus MR; Pruijt JFM; van de Loosdrecht AA; Beeker A
    Transfus Clin Biol; 2023 Aug; 30(3):314-318. PubMed ID: 37061177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C; Clissa C; Stanzani M
    Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.
    Du Y; Long Z; Chen M; Han B; Hou B; Feng F
    Acta Haematol; 2017; 138(2):119-128. PubMed ID: 28866669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E; Kantarjian HM; Koller C; Taher A
    Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron overload in myelodysplastic syndromes: diagnosis and management.
    List AF
    Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Iron overload and myelodysplastic syndromes].
    Rose C; Cambier N; Mahieu M; Ernst O; Fenaux P
    Transfus Clin Biol; 2001 Oct; 8(5):422-32. PubMed ID: 11729396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital.
    Bauduer F; Recanzone H
    Transfus Clin Biol; 2020 Aug; 27(3):128-132. PubMed ID: 32561328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
    Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
    Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
    Leitch HA; Gattermann N
    Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study.
    Cancado R; Watman NP; Lobo C; Chona Z; Manzur F; Traina F; Park M; Drelichman G; Zarate JP; Marfil L
    Hematology; 2018 Oct; 23(9):676-682. PubMed ID: 29663858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron overload in patients with myelodysplastic syndromes: An updated overview.
    Moukalled NM; El Rassi FA; Temraz SN; Taher AT
    Cancer; 2018 Oct; 124(20):3979-3989. PubMed ID: 29905937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.